Literature DB >> 26141460

Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.

Imre F Schene1, Viera Kalinina Ayuso2, Monique de Sain-van der Velden3, Koen L I van Gassen4, Inge Cuppen5, Peter M van Hasselt1, Gepke Visser6.   

Abstract

Neuraminidase deficiency (mucolipidosis I, sialidosis types I and II, cherry-red spot myoclonus syndrome) is a lysosomal storage disorder with an expanding clinical phenotype. Here, we report the striking diagnostic history of late-onset neuraminidase deficiency in two sisters, currently aged 14 (patient 1) and 15 (patient 2).Patient 1 was referred for evaluation of her vision after a traffic accident. During this examination, nummular cataract, macular cherry-red spot, and optic nerve atrophy were seen. Furthermore, tremors were noticed in her arms and legs. This combination suggested a lysosomal storage disorder. Her family history revealed an older sister, patient 2, who had a long history of unexplained neurologic symptoms; she was under unsuccessful treatment for conversion disorder. Patient 2 showed identical ophthalmological findings. In retrospect, she had presented with avascular osteonecrosis of the right femur head at age 9.Urinary oligosaccharide patterns and enzyme activity revealed neuraminidase deficiency in both patients. Urinary-bound sialic acid levels were normal. Sequencing of NEU1 demonstrated two known compound heterozygous mutations (c.1195_1200dup p.His399_Tyr400dup; c.679G>A, p.Glu227Arg).The substantial time window between onset of typical symptoms and diagnosis in patient 2 suggests inadequate awareness of lysosomal storage disorders among clinicians. Of special interest is the observation that normal urinary sialic acid levels do not exclude neuraminidase deficiency. Urinary oligosaccharide screening is essential to diagnosis in such cases. In addition, patient 2 is the fourth case in the literature with a history of femur head necrosis. Bone defects might therefore be an early manifestation of late-onset neuraminidase deficiency.

Entities:  

Year:  2015        PMID: 26141460      PMCID: PMC5059187          DOI: 10.1007/8904_2015_472

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  12 in total

Review 1.  Sialidosis: a review of human neuraminidase deficiency.

Authors:  J A Lowden; J S O'Brien
Journal:  Am J Hum Genet       Date:  1979-01       Impact factor: 11.025

2.  Separation of glycoprotein-derived oligosaccharides by thin-layer chromatography.

Authors:  E W Holmes; J S O'Brien
Journal:  Anal Biochem       Date:  1979-02       Impact factor: 3.365

3.  Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.

Authors:  Melissa Wasserstein; James Godbold; Margaret M McGovern
Journal:  J Inherit Metab Dis       Date:  2012-06-21       Impact factor: 4.982

4.  Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis.

Authors:  E J Bonten; W F Arts; M Beck; A Covanis; M A Donati; R Parini; E Zammarchi; A d'Azzo
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

Review 5.  Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2005-04

6.  Quantification of free and total sialic acid excretion by LC-MS/MS.

Authors:  Maria van der Ham; Berthil H C M T Prinsen; Jan G M Huijmans; Nicolaas G G M Abeling; Bert Dorland; Ruud Berger; Tom J de Koning; Monique G M de Sain-van der Velden
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-11-22       Impact factor: 3.205

7.  Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex.

Authors:  K E Lukong; M A Elsliger; Y Chang; C Richard; G Thomas; W Carey; A Tylki-Szymanska; B Czartoryska; T Buchholz; G R Criado; S Palmeri; A V Pshezhetsky
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

Review 8.  Expanding sialidosis spectrum by genome-wide screening: NEU1 mutations in adult-onset myoclonus.

Authors:  Laura Canafoglia; Angela Robbiano; Davide Pareyson; Ferruccio Panzica; Lorenzo Nanetti; Anna Rita Giovagnoli; Anna Venerando; Cinzia Gellera; Silvana Franceschetti; Federico Zara
Journal:  Neurology       Date:  2014-05-07       Impact factor: 9.910

9.  Oligosaccharide analysis in urine by maldi-tof mass spectrometry for the diagnosis of lysosomal storage diseases.

Authors:  Baoyun Xia; Ghazia Asif; Leonard Arthur; Muhammad A Pervaiz; Xueli Li; Renpeng Liu; Richard D Cummings; Miao He
Journal:  Clin Chem       Date:  2013-05-15       Impact factor: 8.327

10.  Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies.

Authors:  Isaac J Nijman; Joris M van Montfrans; Marlous Hoogstraat; Marianne L Boes; Lisette van de Corput; Ellen D Renner; Patrick van Zon; Stef van Lieshout; Martin G Elferink; Mirjam van der Burg; Clementien L Vermont; Bert van der Zwaag; Esther Janson; Edwin Cuppen; Johannes K Ploos van Amstel; Marielle E van Gijn
Journal:  J Allergy Clin Immunol       Date:  2013-10-15       Impact factor: 10.793

View more
  9 in total

1.  Clinical and genetic characteristics of type I sialidosis patients in mainland China.

Authors:  Rui-Juan Lv; Tao-Ran Li; Yu-Di Zhang; Xiao-Qiu Shao; Qun Wang; Li-Ri Jin
Journal:  Ann Clin Transl Neurol       Date:  2020-05-29       Impact factor: 4.511

2.  Quantifying lymphocyte vacuolization serves as a measure of CLN3 disease severity.

Authors:  Willemijn F E Kuper; Marlies Oostendorp; Brigitte T A van den Broek; Karin van Veghel; Lourens J P Nonkes; Edward E S Nieuwenhuis; Sabine A Fuchs; Tineke Veenendaal; Judith Klumperman; Albert Huisman; Stefan Nierkens; Peter M van Hasselt
Journal:  JIMD Rep       Date:  2020-06-02

3.  Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.

Authors:  Ahmed N Mohammad; Katelyn A Bruno; S Hines; Paldeep S Atwal
Journal:  Mol Genet Metab Rep       Date:  2018-01-12

4.  Genetic and clinical characterization of mainland Chinese patients with sialidosis type 1.

Authors:  Xiaoxu Han; Shijing Wu; Min Wang; Hui Li; Yan Huang; Ruifang Sui
Journal:  Mol Genet Genomic Med       Date:  2020-05-26       Impact factor: 2.183

5.  Compound heterozygous mutations in the neuraminidase 1 gene in type 1 sialidosis: A case report and review of literature.

Authors:  Lan-Xiao Cao; Ying Liu; Zhao-Jun Song; Bao-Rong Zhang; Wen-Ying Long; Guo-Hua Zhao
Journal:  World J Clin Cases       Date:  2021-01-26       Impact factor: 1.337

6.  Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.

Authors:  Binna Seol; Young-Dae Kim; Yee Sook Cho
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

7.  Multigene panel next generation sequencing in a patient with cherry red macular spot: Identification of two novel mutations in NEU1 gene causing sialidosis type I associated with mild to unspecific biochemical and enzymatic findings.

Authors:  Ulrike Mütze; Friederike Bürger; Jessica Hoffmann; Helmut Tegetmeyer; Jens Heichel; Petra Nickel; Johannes R Lemke; Steffen Syrbe; Skadi Beblo
Journal:  Mol Genet Metab Rep       Date:  2016-12-01

8.  Generation of human induced pluripotent stem cells (hIPSCs) from sialidosis types I and II patients with pathogenic neuraminidase 1 mutations.

Authors:  Min-Joon Han; Ida Annunziata; Jason Weesner; Yvan Campos; Muneeb Salie; Carla O'Reilly; Alessandra d'Azzo
Journal:  Stem Cell Res       Date:  2020-05-06       Impact factor: 2.020

9.  Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.

Authors:  Rosario Mosca; Diantha van de Vlekkert; Yvan Campos; Leigh E Fremuth; Jaclyn Cadaoas; Vish Koppaka; Emil Kakkis; Cynthia Tifft; Camilo Toro; Simona Allievi; Cinzia Gellera; Laura Canafoglia; Gepke Visser; Ida Annunziata; Alessandra d'Azzo
Journal:  J Clin Med       Date:  2020-03-04       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.